Provided by Tiger Trade Technology Pte. Ltd.

Adlai Nortye Biopharma Co. Ltd.

15.21
+0.12000.80%
Post-market: 15.13-0.0800-0.53%19:30 EDT
Volume:228.74K
Turnover:3.58M
Market Cap:979.49M
PE:-26.92
High:16.00
Open:15.32
Low:15.20
Close:15.09
52wk High:17.25
52wk Low:0.8786
Shares:64.40M
Float Shares:45.14M
Volume Ratio:0.90
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5649
EPS(LYR):-1.1111
ROE:-20.23%
ROA:-8.70%
PB:4.56
PE(LYR):-13.69

Loading ...

Adlai Nortye Doses First Patient in Phase I Trial for Solid Tumors

MT Newswires Live
·
Sep 08

Adlai Nortye doses first patient in AN4035 trial

TIPRANKS
·
Sep 08

Adlai Nortye Wins FDA IND Clearance for An4035 ADC Trial Expansion to US

Reuters
·
Sep 08

Adlai Nortye Group - to File Ind Application for An4035 with China Nmpa

THOMSON REUTERS
·
Sep 08

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA Ind Clearance for An4035, a First-in-Class Pan-Ras(on) Inhibitor-Based ADC

THOMSON REUTERS
·
Sep 08

Adlai Nortye assumed with a Buy at Lucid Capital

TIPRANKS
·
Sep 08

Adlai Nortye's KRAS Opportunity Further Validated by GSK-Hutchmed Deal, Oppenheimer Says

MT Newswires Live
·
Sep 04

Oppenheimer Sticks to Their Buy Rating for Adlai Nortye Ltd. Sponsored ADR (ANL)

TIPRANKS
·
Aug 27

Major Insider Move Shakes Up Adlai Nortye’s Market Narrative

TIPRANKS
·
Aug 27

Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes

TIPRANKS
·
Aug 26

Prince Harry, Elton John and other celebrities hit with initial $13 million bill after losing case against UK tabloid

CNN Business
·
Aug 21

Analysts’ Opinions Are Mixed on These Healthcare Stocks: US Physical Therapy (USPH) and Adlai Nortye Ltd. Sponsored ADR (ANL)

TIPRANKS
·
Aug 15

Earnings Flash (ANL) Adlai Nortye Posts H1 Revenue $13.1M

MT Newswires Live
·
Aug 14

Adlai Nortye FY26 H1 Net Loss Narrows 70.9% to Us$5.3 Million; Revenue Turns to Us$13.1 Million

Reuters
·
Aug 14

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

THOMSON REUTERS
·
Aug 14

Adlai Nortye Director Lars Erik Birgerson Files Initial Beneficial Ownership Statement

Reuters
·
Aug 04

Adlai Nortye Receives Ethics Approval to Begin Phase 1 Trial of Cancer Drug AN4035

MT Newswires Live
·
Aug 03

Adlai Nortye - in Process of Ind Submissions for An4035 to U.S. FDA and China Nmpa

THOMSON REUTERS
·
Aug 03

Adlai Nortye Announces Clinical Trial Notification Submission and Hrec Approval for the Phase I Clinical Trial of Pan-Ras(on) Inhibitor ADC An4035 in Australia

THOMSON REUTERS
·
Aug 03

Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway

TIPRANKS
·
Jul 27